ONCAlert | 2018 Gastrointestinal Cancers Symposium

Head and Neck Cancers MORE >>

Tipifarnib demonstrated encouraging antitumor activity among patients with HRAS-mutant head and neck squamous cell carcinoma (HNSCC), according to preliminary results of an ongoing phase II proof-of-concept trial (NCT02383927).

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.